---
title: "INKON Life released its 2024 annual performance, with a net profit attributable to the parent company of 115 million yuan, an increase of 14.92%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233641301.md"
description: "INKON Life released its 2024 annual report, with operating revenue of 1.559 billion yuan, a year-on-year increase of 6.01%; net profit attributable to the parent company of 115 million yuan, a year-on-year increase of 14.92%. The net profit excluding non-recurring gains and losses was 83.3721 million yuan, a year-on-year decrease of 19.46%. The basic earnings per share were 0.18 yuan. Medical service revenue was 1.192 billion yuan, a year-on-year increase of 3.76%; oncology revenue increased by 17%"
datetime: "2025-03-28T13:12:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233641301.md)
  - [en](https://longbridge.com/en/news/233641301.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233641301.md)
---

# INKON Life released its 2024 annual performance, with a net profit attributable to the parent company of 115 million yuan, an increase of 14.92%

According to the Zhitong Finance APP, INKON Life (300143.SZ) released its 2024 annual report, showing an operating income of 1.559 billion yuan, a year-on-year increase of 6.01%. The net profit attributable to shareholders of the listed company was 115 million yuan, a year-on-year increase of 14.92%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 83.3721 million yuan, a year-on-year decrease of 19.46%. The basic earnings per share were 0.18 yuan.

During the reporting period, the company's medical services generated revenue of 1.192 billion yuan, a year-on-year increase of 3.76%; outpatient visits reached 496,658, a year-on-year increase of 4%, and inpatient admissions reached 48,355, a year-on-year increase of 6%, reflecting the hospital's upgraded ability to attract patients; during the reporting period, tumor revenue increased by 17%, demonstrating the results of the tumor ecosystem evolution; the volume of tertiary and quaternary surgeries continued to increase by 2% year-on-year on a high base, reflecting the high quality of the hospital's technical level in various disciplines

### Related Stocks

- [300143.CN](https://longbridge.com/en/quote/300143.CN.md)

## Related News & Research

- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [CMI adopts orphan drug field with dedicated center of excellence](https://longbridge.com/en/news/296242891.md)
- [Capella University Announces Appointment of Oncology Leader Dr. Saro Sarkisian to Board of Trustees | STRA Stock News](https://longbridge.com/en/news/296481766.md)
- [Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands](https://longbridge.com/en/news/296027938.md)
- [11:25 ETILD Day 2026 Spotlights Precision Medicine's Potential to Transform Patient Care](https://longbridge.com/en/news/296512797.md)